Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Uniflu
- Development stage
- Phase 1
- Lead developer
- VA Pharma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Uniflu is a recombinant universal influenza vaccine developed by VA Pharma Limited Liability Company. It is designed to induce immunity against a broad range of influenza viruses. The vaccine is currently being investigated in healthy volunteers to assess its reactogenicity, safety, and immunogenicity.
02
Targets
M2e (Influenza A matrix protein 2 ectodomain)
Beyond the preview
Go deeper on Uniflu.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Uniflu.